| Autor: |
Lorentzen JA; Department of Pathology, Oslo University Hospital, Oslo, Norway.; University of Oslo, Oslo, Norway., Grzyb K; Department of Pathology, Oslo University Hospital, Oslo, Norway., De Angelis PM; Department of Pathology, Oslo University Hospital, Oslo, Norway., Hoff G; University of Oslo, Oslo, Norway.; Department of Medicine, Telemark Hospital, Skien, Norway.; Cancer Registry of Norway, Oslo, Norway., Eide TJ; Department of Pathology, Oslo University Hospital, Oslo, Norway.; University of Oslo, Oslo, Norway., Andresen PA; Department of Pathology, Oslo University Hospital, Oslo, Norway. |
| Abstrakt: |
Data are limited on oncogene mutation frequencies in polyps from principally asymptomatic participants of population-based colorectal cancer screening studies. In this study, DNA from 204 polyps, 5 mm or larger, were collected from 176 participants of the NORCCAP screening study and analyzed for mutations in KRAS, BRAF, and PIK3CA including the rarely studied KRAS exons 3 and 4 mutations. KRAS mutations were identified in 23.0% of the lesions and were significantly associated with tubulovillous adenomas and large size. A significantly higher frequency of KRAS mutations in females was associated with mutations in codon 12. The KRAS exon 3 and 4 mutations constituted 23.4% of the KRAS positive lesions, which is a larger proportion compared to previous observations in colorectal cancer. BRAF mutations were identified in 11.3% and were associated with serrated polyps. None of the individuals were diagnosed with de novo or recurrent colorectal cancer during the follow-up time (median 11.2 years). Revealing differences in mutation-spectra according to gender and stages in tumorigenesis might be important for optimal use of oncogenes as therapeutic targets and biomarkers. |
